Sofosbuvir / Ledipasvir Cures More than 90% of Genotype 1 Hepatitis C

Gilead Sciences this week announced sustained virological response rates from the Phase 3 ION trials testing a combination pill containing its newly approved HCV polymerase inhibitor sofosbuvir (Sovaldi) plus the NS5A inhibitor ledipasvir. Across the 3 studies, sofosbuvir/ledipasvir taken for 8 or 12 weeks cured more than 90% of treatment-naive and treatment-experienced genotype 1 patients.

مژده برای مبتلایان دو عفونت ویروسی با اچ آی وی و هپاتیت سی و یا بیماران مبتلا به ویروس هپاتیت سی. با تائید یک داروی ترکیبی جدید با نام Sofosbuvir/Ledipasvir از سوی پزشکان میتوان بیش از 90 درصد و به تائید شرکت دارویی Gilead اینک میتوان قریب به 94 درصد سخت ترین گروه هپاتیت سی ژن یک را نیز در مدت 8 هفته شفا داد.

Sofosbuvir (Image: Gilead Sciences)

Sofosbuvir (Image: Gilead Sciences)

The U.S. Food and Drug Administration this month approved sofosbuvir for use with ribavirin alone for people with HCV genotype 2 or 3, or as an add-on to pegylated interferon/ribavirin for those with genotype 1. While the agency said a longer course of sofosbuvir/ribavirin could be used for genotype 1 patients who cannot tolerate interferon, many still await more effective and shorter duration interferon-free regimens.
Gilead said it expects to request approval of the sofosbuvir/ledipasvir coformulation in early 2014, putting it on track for approval by the end of next year.

continue reading / weiterlesen / ادامه مطلب